Company Description
Zai Lab Limited develops and commercializes products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; VYVGART, a human IgG1 antibody fragment for myesthenia gravis; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; Qinlock to treat gastrointestinal stromal tumors; Xacduro, a combination of a beta-lactam antibiotic (sulbactam) and a beta-lactamase inhibitor (durlobactam) for the treatment of serious infections caused by acinetobacter; and Augtyro, a tyrosine kinase inhibitor ROS1 oncogenic fusions.
The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and its immunology, neuroscience, and infectious disease pipeline includes efgartigimod and xanomeline and trospium chloride.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.
The company was incorporated in 2013 and is based in Shanghai, China.
| Country | China |
| Founded | 2013 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,869 |
| CEO | Ying Du |
Contact Details
Address: Jinchuang Plaza, Building 1, Fourth Floor Shanghai, 201210 China | |
| Phone | 86 21 6163 2588 |
| Website | zailaboratory.com |
Stock Details
| Ticker Symbol | ZLAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704292 |
| CUSIP Number | 98887Q104 |
| ISIN Number | US98887Q1040 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
| Joshua L. Smiley | President and Chief Operating Officer |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research and Development |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer |
| Christine Chiou | Senior Vice President and Head of Investor Relations |
| Frazor Titus Edmondson III, J.D. | Chief Legal Officer and Joint Corporate Secretary |
| Dr. Jonathan J. Wang MBA, Ph.D. | Chief Business Officer |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Research & Development |
| Tong Zhu | Chief Commercial Officer of Greater China |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 28, 2025 | 144 | Filing |
| Feb 28, 2025 | 144 | Filing |
| Feb 28, 2025 | 144 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |